AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29363437 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-step presentation of automated procedural guidance
Number of subjects: 0
Study 29363437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 25918755 — intervention group
Group type: EXPERIMENTAL
Intervention: AV eyeglasses
Number of subjects: 49
Study 25918755 — intervention group
Group type: COMPARATOR
Intervention: No AV eyeglasses
Number of subjects: 49
Study 24041436 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based interactive simulation
Number of subjects: 44
Study 24041436 — intervention group
Group type: COMPARATOR
Intervention: High-fidelity hands-on simulation
Number of subjects: 44
Study 21196669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1mg/kg intravenously at induction of anesthesia)
Number of subjects: 80
Study 21196669 — intervention group
Group type: COMPARATOR
Intervention: Control (saline, equal volume to ketamine)
Number of subjects: 80
Study 18538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients with dilated cardiomyopathy
Number of subjects: 5
Study 18538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy
Number of subjects: 5
Study 18538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients after myocardial infarction
Number of subjects: 5
Study 18538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from ICD trials in older patients
Number of subjects: 5
Study 18538192 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of recurrent ventricular arrhythmias in a patient with an ICD
Number of subjects: 5
Study 16823727 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 59
Study 16823727 — intervention group
Group type: COMPARATOR
Intervention: Insulin as part
Number of subjects: 59
Study 14641967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate with ascorbic acid (4:1 molar ratio)
Number of subjects: 10
Study 14641967 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 10
Study 14641967 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate with Na2EDTA (1:1 molar ratio)
Number of subjects: 10
Study 14641967 — intervention group
Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 10
Study 10688392 — intervention group
Group type: EXPERIMENTAL
Intervention: Penciclovir cream
Number of subjects: 541
Study 10688392 — intervention group
Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 541
Study 8839906 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 152
Study 8839906 — intervention group
Group type: COMPARATOR
Intervention: 2 mg tropisetron
Number of subjects: 152
Study 1500686 — intervention group
Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (ly‐IFN) at a dose of 5 MU/m2 i.m. three times a week for 6 months
Number of subjects: 18
Study 1500686 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 18
Study 1500686 — intervention group
Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (ly‐IFN)
Number of subjects: 18
Study 6391415 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bracing in supination (FUSU)
Number of subjects: 145
Study 6391415 — intervention group
Group type: COMPARATOR
Intervention: Dorsal plaster immobilization (DPI)
Number of subjects: 145
Study 31272883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 31272883 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study 30536163 — intervention group
Group type: COMPARATOR
Intervention: Apalutamide
Number of subjects: 0
Study 30536163 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 0
Study 30536163 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone and prednisone
Number of subjects: 0
Study 27548898 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment (PST)
Number of subjects: 85
Study 27548898 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to physician
Number of subjects: 85
Study 27548898 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 85
Study 24268105 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 223
Study 24268105 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management with interventional therapy
Number of subjects: 223
Study 24268105 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 223
Study 22548767 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (10 mg once daily)
Number of subjects: 454
Study 22548767 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg twice daily)
Number of subjects: 454
Study 22548767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg three times daily)
Number of subjects: 454
Study 22548767 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (50 mg three times daily)
Number of subjects: 454
Study 19918198 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-layered long spineboard
Number of subjects: 30
Study 19918198 — intervention group
Group type: COMPARATOR
Intervention: Rigid long spineboard
Number of subjects: 30
Study 19918198 — intervention group
Group type: COMPARATOR
Intervention: Vacuum mattress
Number of subjects: 30
Study 17274349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intervention group (monthly educational campaign)
Number of subjects: 16
Study 17274349 — intervention group
Group type: COMPARATOR
Intervention: Seasonal intervention group (massive educational campaign before winters)
Number of subjects: 16
Study 16197821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) using urokinase
Number of subjects: 350
Study 16197821 — intervention group
Group type: EXPERIMENTAL
Intervention: New techniques including sonothrombolysis, angiojet aspiration, and laser recanalization
Number of subjects: 350
Study 16197821 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 350
Study 12193148 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 0
Study 12193148 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 0
Study 12193148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish/safflower oil
Number of subjects: 0
Study 12193148 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 10388371 — intervention group
Group type: EXPERIMENTAL
Intervention: SMFP dentifrice containing CaCl2
Number of subjects: 8
Study 10388371 — intervention group
Group type: EXPERIMENTAL
Intervention: SMFP dentifrice
Number of subjects: 8
Study 10388371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 micrograms/kg followed by 0.5 microgram.kg‐1.h‐1 (group 1)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg followed by 1 microgram.kg‐1.h‐1 (group 2)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg followed by 2 micrograms.kg‐1.h‐1 (group 3)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 micrograms/kg (group 1)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg (group 2)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg (group 3)
Number of subjects: 50
Study 9054246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (all groups)
Number of subjects: 50
Study 2523965 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 64
Study 2523965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 1020047 — intervention group
Group type: EXPERIMENTAL
Intervention: 131Cs scanning
Number of subjects: 283
Study 1020047 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 283
Study 1020047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination + 131Cs scanning
Number of subjects: 283
Study 31260676 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 68
Study 31260676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 27771796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pelvic lymphadenectomy (PLND)
Number of subjects: 190
Study 27771796 — intervention group
Group type: COMPARATOR
Intervention: No surgery (no-PLND)
Number of subjects: 190
Study 26452713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 500
Study 26452713 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (initially randomized)
Number of subjects: 500
Study 24365274 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnosis
Number of subjects: 223
Study 24365274 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 223
Study 22234002 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 28
Study 22234002 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 28
Study 19787608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) injection 2.5 mg 3-5 days before operation
Number of subjects: 40
Study 19787608 — intervention group
Group type: COMPARATOR
Intervention: No injection before operation (noninjected group)
Number of subjects: 40
Study 16413895 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification loupes
Number of subjects: 59
Study 16413895 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope
Number of subjects: 59
Study 15545877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-labeled antigranulocyte monoclonal antibody fragment Fab'2 (SMab, Leukoscan); 20 mCi (740 MBq) injected, scans obtained within 3 and 8 hours post-injection.
Number of subjects: 117
Study 11727205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IGI)
Number of subjects: 71
Study 11727205 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 71
Study 9450166 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) inhalation therapy (400 micrograms/day)
Number of subjects: 42
Study 9450166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BDP inhalation therapy)
Number of subjects: 42
Study 7954563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (patients with rheumatic mitral valve disease in atrial fibrillation)
Number of subjects: 61
Study 7954563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (patients with rheumatic mitral valve disease in sinus rhythm)
Number of subjects: 61
Study 7954563 — intervention group
Group type: COMPARATOR
Intervention: Control group for group 1 (36 patients with nonrheumatic atrial fibrillation)
Number of subjects: 61
Study 7954563 — intervention group
Group type: COMPARATOR
Intervention: Control group for group 2 (22 patients with various cardiovascular diseases and sinus rhythm)
Number of subjects: 61
Study 3631765 — intervention group
Group type: EXPERIMENTAL
Intervention: Periumbilical peritoneal lavage
Number of subjects: 53
Study 3631765 — intervention group
Group type: COMPARATOR
Intervention: Infraumbilical peritoneal lavage
Number of subjects: 53
Study 29322434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 hours
Number of subjects: 100
Study 29322434 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (control group)
Number of subjects: 100
Study 29322434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC)
Number of subjects: 100
Study 29322434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) and control group
Number of subjects: 100
Study 26919554 — intervention group
Group type: EXPERIMENTAL
Intervention: Wraparound eyeglasses in addition to medical treatment (group 1, n = 39)
Number of subjects: 70
Study 26919554 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (group 2, n = 31)
Number of subjects: 70
Study 24749723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled intervention promoting delirium prevention, recognition, and management
Number of subjects: 19949
Study 24749723 — intervention group
Group type: COMPARATOR
Intervention: Control group (aged 80 and older admitted before April 26, 2010)
Number of subjects: 19949
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 70 mg every 2 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 105 mg every 2 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 140 mg every 2 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 280 mg every 4 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 350 mg every 4 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 420 mg every 4 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 406
Study 23141812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 406
Study 20440092 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone administered immediately after surgery
Number of subjects: 78
Study 20440092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 78
Study 20440092 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 78
Study 20440092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received Etorikoxib 120 mg 30 minutes before operation
Number of subjects: 78
Study 18305291 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind antidepressant treatment
Number of subjects: 24
Study 16006206 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention program based on protection motivation theory (PMT)
Number of subjects: 480
Study 16006206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 480
Study 12439162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.51 mg/kg)
Number of subjects: 49
Study 12439162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (1.41 mg/kg)
Number of subjects: 49
Study 12439162 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 49
Study 10363221 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Choices program
Number of subjects: 3677
Study 8624226 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer pre-brush mouthrinse (0.03% triclosan and 0.13% PVM/MA copolymer)
Number of subjects: 121
Study 8624226 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-brush mouthrinse
Number of subjects: 121
Study 2140489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 60 mg
Number of subjects: 25
Study 2140489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 40 mg
Number of subjects: 25
Study 2140489 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil 10 mg
Number of subjects: 25
Study 2140489 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil 20 mg
Number of subjects: 25
Study 415330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of 95% ethanol
Number of subjects: 10
Study 415330 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of delta9 tetrahydrocannabinol (THC)
Number of subjects: 10
Study 415330 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of delta9 tetrahydrocannabinol (THC)
Number of subjects: 10
Study 415330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of 95% ethanol together with 15 mg of THC
Number of subjects: 10
Study 415330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31072317 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Dual Task (EMDT) in combination with usual care
Number of subjects: 90
Study 31072317 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 90
Study 28125809 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/NaF/SnCl2 solution twice a day
Number of subjects: 12
Study 28125809 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/NaF/SnCl2 solution once a day
Number of subjects: 12
Study 28125809 — intervention group
Group type: COMPARATOR
Intervention: NaF solution (positive control, 500 ppm F‐, pH 4.5)
Number of subjects: 12
Study 28125809 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (negative control)
Number of subjects: 12
Study 25501988 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg
Number of subjects: 28
Study 25501988 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg
Number of subjects: 28
Study 25501988 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg and 600 mg
Number of subjects: 28
Study 22505131 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching (2 minutes, 4 sets of 5-second isometric hamstring contraction followed by 5 seconds of passive static stretch of the quadriceps and 5 seconds isometric quadriceps contraction)
Number of subjects: 12
Study 22505131 — intervention group
Group type: COMPARATOR
Intervention: Control session (walking at a comfortable speed for 2 minutes)
Number of subjects: 12
Study 21875913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel for 6 months
Number of subjects: 2800
Study 21875913 — intervention group
Group type: EXPERIMENTAL
Intervention: OTR <208 P2Y12 reaction units
Number of subjects: 2800
Study 21875913 — intervention group
Group type: EXPERIMENTAL
Intervention: OTR <208 P2Y12 reaction units (adjusted)
Number of subjects: 2800
Study 19905900 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the Stockholm trial
Number of subjects: 115
Study 19905900 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in the Stockholm trial
Number of subjects: 115
Study 17023769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 microg/kg in 10 minutes followed by an infusion rate of 0.2 microg/kg/hr)
Number of subjects: 40
Study 17023769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 17023769 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 14615470 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR1031 under fasted conditions
Number of subjects: 8
Study 14615470 — intervention group
Group type: COMPARATOR
Intervention: HMR1031 under fed conditions
Number of subjects: 8
Study 11127250 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) 12 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Number of subjects: 150
Study 11127250 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) 18 mg/kg daily plus Sodium Stibogluconate (SB) 20 mg/kg daily for 21 days
Number of subjects: 150
Study 11127250 — intervention group
Group type: COMPARATOR
Intervention: Sodium Stibogluconate (SB) alone for 30 days
Number of subjects: 150
Study 9263282 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 84
Study 9263282 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous, isoenergetic control
Number of subjects: 84
Study 8474811 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula with 12.7 mg/L iron
Number of subjects: 347
Study 8474811 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula with 7.4 mg/L iron
Number of subjects: 347
Study 8474811 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 347
Study 3082347 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg SCG aerosol
Number of subjects: 11
Study 3082347 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SCG aerosol
Number of subjects: 11
Study 3082347 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg SCG aerosol
Number of subjects: 11
Study 3082347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3082347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised SCG (10 g l‐1)
Number of subjects: 11
Study 30467952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly increased uACR (≥10 mg/g <30 mg/g)
Number of subjects: 2176
Study 30467952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly increased uACR (≥10 mg/g <30 mg/g) in nonwhites
Number of subjects: 2176
Study 28464496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pibrentasvir
Number of subjects: 0
Study 28464496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pibrentasvir with ritonavir
Number of subjects: 0
Study 27284115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using the frontal/executive program for about six months
Number of subjects: 15
Study 27284115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using the frontal/executive program
Number of subjects: 15
Study 27284115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 24493413 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed (123)I-MIBG scintigraphy
Number of subjects: 78
Study 24493413 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 78
Study 24493413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of delayed (123)I-MIBG scintigraphy and FMD
Number of subjects: 78
Study 24493413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78